Search

Your search keyword '"Ronzoni M"' showing total 190 results

Search Constraints

Start Over You searched for: Author "Ronzoni M" Remove constraint Author: "Ronzoni M" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
190 results on '"Ronzoni M"'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

5. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

6. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

8. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

9. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

12. Signs and symptoms of COVID-19 in patients with multiple sclerosis

13. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

14. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

16. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study

17. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

18. Signs and symptoms of COVID-19 in patients with multiple sclerosis

19. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

20. The Italian multiple sclerosis register

21. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

22. PO-1214 Toxicity profile of adjuvant hypofractionated Image-Guided Radiotherapy in biliary tract carcinoma

23. PO-1212 Outcome of adjuvant hypofractionated radiotherapy concomitant to chemotherapy in bile duct carcinoma

25. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

26. Detection of lung hypoperfusion in Covid-19 patients during recovery by digital imaging quantification

28. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

30. PD-0539: Chemo-modulation of rectal cancer pathological response: prediction of an early regression index

31. 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment

32. 399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial

33. Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial

35. Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO

36. Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

37. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

38. Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

39. EP-1459 Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer

40. PO-0816 Adaptive radiotherapy concomitant with chemotherapy as preoperative treatment for rectal cancer

41. Activity and safety of cetuximab plus modified folfoxiri followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized phase 2 clinical trial

42. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

44. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

45. Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

46. OC.13.1 ASSOCIATION OF GERMLINE GENE MUTATIONS IN EARLY ONSET GASTROINTESTINAL CANCERS WITH NEGATIVE FAMILY HISTORY

47. Correction to: Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

48. Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients

49. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.ANNALS OF ONCOLOGY, ISSN: 0923-7534

50. FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial

Catalog

Books, media, physical & digital resources